摘要
目的研究坎地沙坦和福辛普利联合治疗高血压伴早期糖尿病肾病(DN)及糖尿病高血压的疗效。方法随机选择门诊长期随访的2型糖尿病并早期DN及糖尿病高血压患者60例,随机分为福辛普利组、坎地沙坦组与联合治疗组(福辛普利+坎地沙坦),观察16周。检测各组治疗前后尿素氮(BUN)、血清肌酐(SCr)及尿清蛋白排泄率(UAER)水平;并监测其治疗前后平均动脉压(MAP)水平。结果3组治疗前后MAP水平差异无统计学意义,但治疗后尿清蛋白排泄率均较治疗前明显下降(P<0.05);联合治疗组尿清蛋白排泄率下降最明显(P<0.05)。结论福辛普利和坎地沙坦联合治疗早期糖尿病肾病疗效显著。
Objective To observe the clinical effect of Candesartan combined with Fosinopril in the treatment of diabetic nephropathy (DN).Methods 60 cases with type 2 diabetes along with early nephropathy were randomly divided into 3 groups, which one was treated with Candesartan 4mg daily,another was treated with 10mg daily,and the combined therapy group was treated with Candesartan and Fosinopril.At the beginning and the end of treatment,the renal function,urinary albumin excretion rate(UAER)in 24 hours,and the mean arterial blood pressure(MAP)were measured.Results After 16 weeks treatment,the level of UAER decreased in all groups.More significant in combined group compared with the other two groups with single drug. No severe adverse reaction occured.Conclusion Combination of Candesartan and Fosinopril in the treatment of diabetic nephropathy can significantly decrease urinary protein,then prevent the development of DN,and improve the survival situation of DN patients.
出处
《中国医药指南》
2008年第24期11-12,共2页
Guide of China Medicine
关键词
福辛普利
坎地沙坦
糖尿病肾病
高血压
diabetic nephropathy(DN)
candesartan
fosinopril
urinary albumin excretion rate(UAER)
